Investors focused on the Medical space have likely heard of Patterson Companies (PDCO - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Patterson Companies is a member of our Medical group, which includes 927 different companies and currently sits at #12 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. PDCO is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for PDCO's full-year earnings has moved 14.44% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the latest available data, PDCO has gained about 34.47% so far this year. Meanwhile, the Medical sector has returned an average of 1.17% on a year-to-date basis. This means that Patterson Companies is outperforming the sector as a whole this year.
Looking more specifically, PDCO belongs to the Medical - Dental Supplies industry, which includes 22 individual stocks and currently sits at #53 in the Zacks Industry Rank. On average, this group has gained an average of 11.53% so far this year, meaning that PDCO is performing better in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track PDCO. The stock will be looking to continue its solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Investors focused on the Medical space have likely heard of Patterson Companies (PDCO - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Patterson Companies is a member of our Medical group, which includes 927 different companies and currently sits at #12 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. PDCO is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for PDCO's full-year earnings has moved 14.44% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the latest available data, PDCO has gained about 34.47% so far this year. Meanwhile, the Medical sector has returned an average of 1.17% on a year-to-date basis. This means that Patterson Companies is outperforming the sector as a whole this year.
Looking more specifically, PDCO belongs to the Medical - Dental Supplies industry, which includes 22 individual stocks and currently sits at #53 in the Zacks Industry Rank. On average, this group has gained an average of 11.53% so far this year, meaning that PDCO is performing better in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track PDCO. The stock will be looking to continue its solid performance.
Zacks Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
It’s a little-known chemical company that’s up 65% over last year, yet still dirt cheap. With unrelenting demand, soaring 2022 earnings estimates, and $1.5 billion for repurchasing shares, retail investors could jump in at any time.
This company could rival or surpass other recent Zacks’ Stocks Set to Double like Boston Beer Company which shot up +143.0% in little more than 9 months and NVIDIA which boomed +175.9% in one year.
Free: See Our Top Stock and 4 Runners Up >>
Get the latest research report on PDCO - FREE